TEMPO Commencing a Formal Process for a Significant Investment
The Board of Directors of Nýherji hf. has hired AGC Partners, a global investment bank headquartered in Boston, MA, to initiate a formal process for a significant investment in TEMPO ehf, a wholly-owned Nýherji subsidiary.
Tempo’s solutions enable organizations to plan, optimize, and manage JIRA resources, budget and track project costs, and track and report time for back-office efficiency. The Company’s solutions solve key “white-collar” enterprise pain points around JIRA developer productivity, resource optimization, and time tracking as it unobtrusively collects data on calendars and tool usage in the background for the pre-population of time sheets. Tempo’s time management and budgeting tools have become essential products in the JIRA ecosystem and are well received by CIOs and CFOs looking to gain better clarity into time and resource usage and cost within their organization. Further, Tempo is consistently one of the highest rated and most downloaded add-on application within the Atlassian Marketplace.
Nýherji CEO, Finnur Oddsson, "Tempo's continued growth and success has been fueled by the team‘s singular focus on building a world-class product and organization. Following the development of Tempo Cloud for JIRA and the migration of over 7,000 customers over to Tempo's new cloud services on top of AWS (Amazon Web Services), a number of exciting growth opportunities have opened up, including integration with other cloud services in addition to JIRA by Atlassian. We think now is the right time to enhance Tempo‘s growth with a sophesticated investor that can help take the Company to the next level. For the past year, AGC Partners has advised on the strategic aspects of Tempo's operations and growth strategy and assisted with the general presentation of the Tempo to investors in the technology sector. AGC Partners will now commence Tempo's formal investment process, aiming to attract a financial partner with extensive experience in growing software companies internationally. We believe this will best enable the continuation of product development at Tempo, its revenue growth, and value for owners, employees and customers."
Nýherji is one of Iceland’s largest providers of information technology solutions, offering hardware, software, consultancy, and technical services. Nýherji has over 1,000 clients and helps our customers achieve the best results for their businesses with the help of IT services through our staff's expertise and quality service. Nýherji hf. is registered in NASDAQ OMX Iceland hf. under the symbol NYHR.
Tempo is a leading provider of time management and budgeting software, transforming time and resource tracking for increased back-office efficiency with smart work management solutions. Tempo's customers are companies around the globe, from startups to Fortune 500 companies including BMW, Pfizer, HomeAway, PayPal, Hulu, Dell, Mercedes Benz, Starbucks, and Disney. Tempo is a whole-owned subsidiary of Nýherji Group. Tempo employs around 100 staff, both in Iceland and in North America. Visit www.tempo.io for more information.
For the attention of investors
Nýherji Group wishes to notify investors that statements made in this press release may be based on the current expectations, forecasts and assumptions of the company's executives and not facts subsequently verifiable by the publication of this press release. Such statements are naturally subject to future risks and uncertainties. We wish to notify investors that a number of factors could cause the company's business environment to differ materially from current expectations as assumed in the press release. This press release will not be revised after its publication in this regard. Any statement made in this press release is valid only at the point of its publication, and its validity is restricted in accordance with this clause.
Finnur Oddsson, Nýherji CEO
+354 862 0310
Gunnar Petersen, Nýherji CFO
+354 825 9001
Frederick Joseph at AGC Partners
+001 617 261 4150
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28 | Tiedote
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme